+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Successes and Challenges of NK Immunotherapy. Breaking Tolerance to Cancer Resistance

  • ID: 5146476
  • Book
  • June 2021
  • Elsevier Science and Technology

Successes and Challenges of NK Immunotherapy: Increasing Anti-tumor Efficacy describes the unique therapeutic applications of NK cells to fight cancers and eliminate the bulk and subset of cancer stem cells responsible for metastasis, relapse and recurrences. The book provides information on the development, engineering, mechanisms of action, response to various preclinical models, and applications in various clinical trials. Sections cover the development of highly engineered cytotoxic NK cells, their mechanisms of action, preclinical and clinical applications, the development and application of CAR-NK cells, and new NK-drug conjugates, also emphasizing that activated NK cells can target and kill highly resistant cancer stem cells.

Written by the leading experts on NK immunotherapy worldwide, this is a valuable resource for researchers, clinicians and members of the biomedical field who are interested in understanding novel and efficient therapies to fight cancers.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Note: Product cover images may vary from those shown

Section 1: Modulation of NK Antitumor Activities 1. Engineered Human Pluripotent Stem Cell-Derived NK Cells with Improved Anti-tumor Activity 2. The Cancer NK cell Immunity Cycle 3. Immunometabolic reprogramming of NK cells for immunotherapy of solid tumors 4. Immunoregulation of NK cells: Similarities and Differences Compared to T cells 5. Tracking the decay of TGFb-resistant NK cells identifies an immune clock of innate cell aging

Section 2: Regulation of NK Antitumor Activities 6. Oncolytic virus therapy for cancer; role in activation of NK cells 7. Rendering NK cells resistant to immune suppression: genetic modification with a dominant negative receptor for TGF-Beta 8. Cystatin F, an inhibitor of cysteine cathepsins, regulates the cytotoxicity of NK cells 9. The NCR2-PCNA Immune Checkpoint and Natural Killer-based immunotherapy 10. Tumor derived soluble human NKG2D ligand mediated perturbations in NK cell metabolism and therapeutic implications 11. The expression of high affinity recombinant Fc receptors by engineered natural killer cells to enhance cancer cell killing by ADCC

Section 3: NK Antitumor Immunotherapy 12. The many key functions of Natural Killers cells in premalignant and malignant stages of tumorigenesis; when these gatekeepers are gone or defective anarchy ensues 13. Phenotypic plasticity: the emergence of cancer stem cells and collective cell migration 14. Stem cell-engineered invariant natural killer T cells for cancer immunotherapy 15. Natural killer cells in the glioblastoma stem cell niche microenvironment 16. CAR-redirected Cytokine-Induced Killer lymphocytes against sarcomas 17. The Effect of Natural Killer Cells on HIV-1 Rebound in Humanized Mice

Section 4: NK Antitumor Immunotherapy 2 18. NK cells are innate actors in the immunosurveillance of melanoma 19. Patients with prostate cancer associate with altered features of Natural Killer cells in terms of pro-angiogenic function and M2-like macrophage polarization capacity 20. New therapeutic approaches to target malignant gliomas 21. Mobilizing Human iNKT cells for Cancer Immunotherapies 22. Initial Innate Immune Responses to Tumor Metastasis 23. Regulating NK cell homeostasis and function by tumor associated NKG2D ligand MIC 24. Natural Killer Cells in Cancer Immunotherapy and Oncolytic Virotherapy

Section 5: General Concluding Remarks and Future Perspectives

Note: Product cover images may vary from those shown
Benjamin Bonavida Professor, Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, USA. Benjamin Bonavida, PhD, has been involved in the field of immunology and cancer biology for several decades and has published extensively in the fields of cancer resistance, chemotherapy, immunotherapy, and various molecular approaches to circumvent the resistance of the cancer cells using sensitizing agents. Accordingly, he was the first to publish a book on tumor sensitization in 2008. More recently, Dr. Bonavida is the Series Editor of 3 series published by Elsevier/Academic Press ("Cancer Sensitizing Agents for Chemotherapy,” "Breaking Cancer Resistance to Therapeutic Antibodies,” and "Breaking Tolerance to Anti-Cancer Immunotherapy”) and several books have been published and many are in development. He has published extensively in the field of NK biology and cytotoxicity in the past, and many of these publications were in collaboration with the co-editor Dr. Anahid Jewett. Anahid Jewett National Institute of Health Study Sections, UCLA, USA. Dr. Anahid Jewett, PhD, MPH, is well-known nationally and internationally for her contribution to the field of NK biology, tumor immunology and cancer immunotherapy. She serves on the editorial board of many prestigious journals and has been a reviewer on the board of National Institute of Health study sections. She holds several patents and has published more than 100 high impact journal articles, reviews, commentaries and book chapters in the field of cancer. Dr. Jewett's major contributions to science and NK cell biology were the identification, characterization and the establishment of the concept of split anergy in NK cells, establishment of the role of NK cells in elimination, selection and differentiation of cancer stem cells as well as healthy stem cells, and methods to generate large numbers of super-charged NK cells which are in use currently in clinical trials of cancer patients.
Note: Product cover images may vary from those shown